APLMA Calls for a Unified Approach and Increased Urgency in the Malaria Fight: World Malaria Report 2023 shows rise i...
The WHO World Malaria Report 2023 estimates there were 10 million malaria cases in Asia Pacific in 2022—up 24% from 2021
Dr. Mansukh Mandaviya Delivers Keynote Address at the Asia-Pacific Leaders’ Conclave on Malaria Elimination
Malaria is a social, economic and political challenge that requires the co-operation of all stakeholders
Asia Pacific Remains Vigilant Against Malaria While Increasing Elimination Efforts to Address Gaps in High-Burden Cou...
Countries held the line against malaria, avoiding the worst-case scenario. But we cannot be complacent.
Prime Minister Sogavare of Solomon Islands meets with Asia Pacific Leaders Malaria Alliance Secretariat in Singapore
Prime Minister Hon. Manasseh Sogavare and his delegation met with APLMA to accelerate malaria elimination by 2030.
Asia Pacific Leaders Malaria Alliance Applauds Asia Pacific’s Commitment Towards the Global Fund to Fight AIDS, Tube...
The Global Fund has raised USD 14.25 billion for the next three years to end AIDS, tuberculosis, and malaria. Asia Pacific has shown tremendous leadership by joining the global health community to fight for what counts.
Bhutan and Timor-Leste Share Lessons to Stay on Course to End Malaria By 2025
Ahead of World Malaria Day, a new paper published by The Lancet Regional Health-Western Pacific highlights key lessons drawn from Bhutan and Timor-Leste’s sustained malaria elimination efforts since their re-commitment to the World Health Organizations (WHO) E-2025 initiative last year. It details the approaches adapted by both countries to maintain the spotlight on malaria whilst preventing large COVID-19 outbreaks, as well as policies adopted to eliminate malaria by 2025.
The Asia Pacific Leaders Malaria Alliance and Asia Pacific Malaria Elimination Network Welcome Single-dose Treatment ...
The Asia Pacific Leaders Malaria Alliance (APLMA) and Asia Pacific Malaria Elimination Network (APMEN) welcomes the recently approved (14 March 2022) use of single-dose tafenoquine by the Australian Therapeutic Goods Administration (TGA) for the prevention of relapsing Plasmodium vivax (P. vivax) malaria in children aged 2 years and above.